These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia? Kondziella D; Brenner E; Eyjolfsson EM; Sonnewald U Neurochem Int; 2007 Jan; 50(2):291-301. PubMed ID: 17084946 [TBL] [Abstract][Full Text] [Related]
27. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms. Pietraszek M Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541 [TBL] [Abstract][Full Text] [Related]
28. BL-1020, an oral antipsychotic agent that reduces dopamine activity and enhances GABAA activity, for the treatment of schizophrenia. Fitzgerald PB Curr Opin Investig Drugs; 2010 Jan; 11(1):92-100. PubMed ID: 20047163 [TBL] [Abstract][Full Text] [Related]
29. Elevated plasma γ-aminobutyrate/glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. Cai HL; Zhu RH; Li HD; Zhang XH; Hu L; Yang W; Ye HS Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1273-8. PubMed ID: 20637820 [TBL] [Abstract][Full Text] [Related]
30. [Interaction of neurotransmitters in specific circuits of the brain]. Mora Teruel F An R Acad Nac Med (Madr); 1998; 115(3):653-7; discussion 657-8. PubMed ID: 10208018 [No Abstract] [Full Text] [Related]
31. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Javitt DC Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858 [TBL] [Abstract][Full Text] [Related]
32. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders. Wierońska JM; Pilc A Pharmacol Ther; 2019 Jan; 193():75-82. PubMed ID: 30149102 [TBL] [Abstract][Full Text] [Related]
34. [Brain of patients with chronic schizophrenia and neurotransmitters]. Toru M Seishin Shinkeigaku Zasshi; 2005; 107(10):1015-21. PubMed ID: 16381382 [No Abstract] [Full Text] [Related]
35. Recent advances in atypical antipsychotics. Armer R; Miller DJ Curr Opin Investig Drugs; 2000 Dec; 1(4):481-93. PubMed ID: 11249703 [No Abstract] [Full Text] [Related]
36. Phenotype of schizophrenia: a review and formulation. Tamminga CA; Holcomb HH Mol Psychiatry; 2005 Jan; 10(1):27-39. PubMed ID: 15340352 [TBL] [Abstract][Full Text] [Related]
37. A glutamatergic deficiency model of schizophrenia. Carlsson A; Hansson LO; Waters N; Carlsson ML Br J Psychiatry Suppl; 1999; (37):2-6. PubMed ID: 10211132 [TBL] [Abstract][Full Text] [Related]
38. Dopamine and glutamate dysfunctions in schizophrenia: role of the dopamine D3 receptor. Leriche L; Diaz J; Sokoloff P Neurotox Res; 2004; 6(1):63-71. PubMed ID: 15184107 [TBL] [Abstract][Full Text] [Related]
39. Neurochemical alterations in schizophrenia affecting the putative receptor targets of atypical antipsychotics. Focus on dopamine (D1, D3, D4) and 5-HT2a receptors. Harrison PJ Br J Psychiatry Suppl; 1999; (38):12-22. PubMed ID: 10884896 [No Abstract] [Full Text] [Related]
40. GABA and schizophrenia: a review of basic science and clinical studies. Wassef A; Baker J; Kochan LD J Clin Psychopharmacol; 2003 Dec; 23(6):601-40. PubMed ID: 14624191 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]